CTRI/2022/11/047055尚未招募3 期
A Multicentric, Randomized, Double Blind, Double Dummy, Parallel Group, Comparative, Phase-III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of FDC of Metoprolol succinate 50 mg plus Amlodipine 5 mg plus Telmisartan 40 mg tablets, versus Co administration of Metoprolol succinate 50 mg and Telmisartan 80 mg tablets in subjects with Uncontrolled Essential Hypertension with stable Coronary Artery Disease (CAD).
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 220
- 试验地点
- 11
- 主要终点
- Mean change in SeSBP between baseline and 12 weeks.
研究概览
简要总结
A Multicentric, Randomized, Double Blind, Double Dummy, Parallel Group, Comparative, Phase-III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of FDC of Metoprolol succinate 50 mg + Amlodipine 5 mg + Telmisartan 40 mg tablets, versus Co-administration of Metoprolol succinate 50 mg and Telmisartan 80 mg tablets in subjects with Uncontrolled Essential Hypertension with stable Coronary Artery Disease (CAD)
Trial of 84 days with two arms
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 75.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Male or female subjects aged between 18 and 75 years.
- •2.Subjects of stable coronary artery disease.
- •3.Subjects with the history of uncontrolled essential hypertension with stable coronary artery disease [having seated diastolic BP (SeDBP) 90 to 110 mmHg and seated systolic BP (SeSBP) 140 to 180 mmHg] who is on the stable dose of Metoprolol succinate ER 50 mg plus Telmisartan 40 mg Tablets for at least 4 weeks.
- •4.Subjects who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures.
- •5.Female subjects of childbearing potential must be willing to use acceptable method of contraception or post-menopausal for at least one year or surgically sterile.
排除标准
- •1.Suspected hypersensitivity to either of the study medications or any of the ingredients of the formulation.
- •2.Subjects with EF less than 40% as per Simpson’s method on 2D Echo.
- •3.Subjects diagnosed with Secondary or Malignant Hypertension.
- •4.Surgical or medical condition that, in the judgment of the Investigator, could interfere with absorption, distribution, metabolism, or excretion of the drugs to be used.
- •5.Renal system: Subjects with eGFR more than 60 mL per min per 1.73m2 Subjects with abnormal lab values of Na, K, Mg and Uric acid.
- •normal range: Na Equal to135 to 145 mEq per L, K equal to 3.5 to 5.0 mmol per L, Mg equal to 7 to 12 mg per dL and Uric acid 3.5 to 7.2 mg per dL 6.Hepatic system: Subjects with abnormal Liver Function Test with values more than 2.5 times the upper limit of normal.
- •7.Endocrine system: Subjects with abnormal Thyroid Function Test, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus with HbA1c value greater than 8%.
- •8.Cardiovascular system: Subjects with known case of symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) less than one year or coronary artery bypass graft (CABG) surgery less than one year, sinus node dysfunction and any clinically significant cardiac arrhythmias.
- •Subjects with known case of Stroke.
- •9.Other disease conditions Subject with clinical history of COPD, Bronchial Asthma and Peripheral Vascular disease.
结局指标
主要结局
Mean change in SeSBP between baseline and 12 weeks.
时间窗: Baseline and 12 weeks
The assessment of safety of subjects, comparison of incidence of treatment emergent adverse event (TEAE).
时间窗: Baseline and 12 weeks
次要结局
- Mean change in SeDBP from baseline Time frame: 4, 8 and 12 weeks.(Mean change in SeSBP from baseline Time frame: 4, 8 and 12 weeks.)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
3 期
A multicentric randomized comparative phase III clinical study of FDC of Azelnidipine 16 mg plus Telmisartan 40 mg Film Coated Tablets Versus FDC of Amlodipine 5 mg plus Telmisartan 40 mg tablets in subjects with stage 2 hypertensionCTRI/2022/07/044031Mascot Health Series PVT Ltd212
尚未招募
3 期
A Study of Combination of Efonidipine Hydrochloride Ethanolate 20 mg/20 mg and Metoprolol Succinate ER 25 mg/ 50 mg Tablets Versus Efonidipine Hydrochloride Ethanolate Tablets 20 mg and Metoprolol Succinate ER Tablets 50 mg Monotherapy for the treatment of Hypertension.CTRI/2018/12/016625Ajanta Pharma Ltd300
Unknown
3 期
A Study of Azelnidipine Tablets for the treatment of subjects with HypertensionCTRI/2019/07/020126Synokem Pharmaceuticals Ltd236
已完成
3 期
A Study of Combination of Benidipine plus Telmisartan Tablets for the treatment of subjects with Hypertension.CTRI/2019/12/022455Synokem Pharmaceuticals Ltd240
已完成
3 期
A Phase-III clinical study to compare the Efficacy, Safety and Tolerability of FDC of Telmisartan 40mg plus Bisoprolol 5 mg tablets versus FDC of Telmisartan 40mg plus Metoprolol Succinate ER 50 mg tablets in the treatment of Stage 1 and Stage 2 HypertensionCTRI/2021/11/037926Micro Labs Limited264